10:54 AM EDT, 07/09/2025 (MT Newswires) -- Eli Lilly's ( LLY ) sales of Zepbound probably rose in Q2, boosting earnings and revenue prospects, BofA Securities said Wednesday in a report.

BofA increased its per-share earnings and revenue estimates by a low single-digit percentage,

The long-term driver remains Eli Lilly's ( LLY ) incretin and glucagon-like peptide 1 drugs for obesity and diabetes, including Mounjaro, Zepbound, orforglipron and retatrutide, the report said.

Earnings in Q2 may focus on macro risks, including US drug pricing reforms and trade tariffs, updates on key clinical trials, brand performance and new product rollouts such as Kisunla for Alzheimer's disease and Ebglyss in atopic dermatitis, the report said.

BofA reiterated its buy rating on Eli Lilly's ( LLY ) stock with a $1,000 price target.

Eli Lilly ( LLY ) stock rose 1.2% in recent trading Wednesday.

Price: 786.63, Change: +8.97, Percent Change: +1.15